Education
About Us
Working with TipRanks
Follow Us
Ute Pantke Insider Profile
4 Followers
Ute Pantke, Director at STADA Arzneimittel Aktiengesellschaft, holds ― shares in STADA Arzneimittel Aktiengesellschaft (Ticker: STDAF). Most recently, Ute Pantke Sold $300 shares of STADA Arzneimittel Aktiengesellschaft on Sep 04, 2017 for an estimated value of 23.46K.
Ute Pantke STADA Arzneimittel Aktiengesellschaft (STDAF)Director
STADA Arzneimittel Aktiengesellschaft (STDAF)
Director
Not Ranked
Ute Pantke has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Ute Pantke does not currently own shares as a corporate insider.
A breakdown of Ute Pantke's holdings
Insider Roles
Ute Pantke does not currently hold a role as a corporate insider.
Roles that Ute Pantke holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Ute Pantke
Ute Pantke's Trading History
List of latest transactions for each holding click on a transaction to see Ute Pantke's performance on stock
You May Also Like
Ute Pantke insider profile FAQ
What is the percentage of profitable transactions made by Ute Pantke?
The percentage of profitable transactions made by Ute Pantke is ―.
What is the average return per transaction made by Ute Pantke?
The average return per transaction made by Ute Pantke is ―.
What stocks does Ute Pantke hold?
Ute Pantke holds: STDAF stocks.
What was Ute Pantke’s latest transaction?
Ute Pantke latest transaction was an Informative Sell of $23.46K.
What was Ute Pantke's most profitable transaction?
Ute Pantke’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Ute Pantke's role in STADA Arzneimittel Aktiengesellschaft?
Ute Pantke's role in STADA Arzneimittel Aktiengesellschaft is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.